U.S. Democratic Senator Patty Murray sent a letter to Johnson & Johnson on Tuesday seeking information related to allegations in a Reuters Special Report that the healthcare company knew about the presence of asbestos in its talc-based baby powder. The letter addressed to J&J Chief … More
Main Navigation Menu
➤ Pharmaceutical Drug Injury Lawsuits
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ GenX Water Contamination Cancer Cases
➤ Breast Implants Lymphoma Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
➤ About the Law Offices of Thomas J. Lamb
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Lemtrada Drug Safety Update: Use Restrictions And Patient Monitoring For Side Effects
On May 17, 2019 the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) issued this Lemtrada Drug Safety Update, “Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements”, we get this … More
U.S. states sue EPA for stricter asbestos rules
Ten U.S. states and Washington, D.C. sued the Environmental Protection Agency (EPA) to begin working on rules to tighten oversight of asbestos, and reduce the health risks that the substance poses to the public. The attorneys general from California and Massachusetts, Xavier Becerra and Maura … More
GenX Levels in Water: Is the Cape Fear River Region Still at Risk?
Recap on GenX Contamination GenX contamination has been on the worried minds of many people living in the Cape Fear River region for several years now. Though GenX is still present, it is reportedly far less than what it has been in previous years. WHQR of Wilmington has recently published a … More
Another Antiangiogenic Failure in Unresectable Mesothelioma
The addition of nintedanib (Ofev) to standard of care pemetrexed (Alimta) plus cisplatin failed to delay disease progression in patients with unresectable malignant pleural mesothelioma, according to phase III results of the LUME-Meso study. After a median treatment duration of more than 5 … More
Actemra Liver Injury Risks Warnings Added To Drug Label In June 2019
The FDA sent an email on June 13, 2019 about Drug Safety-related Labeling Changes (SrLC) which alerted us to a revised version of the Actemra Prescribing Information document used in the US. Upon review of this new section added to the “Warnings and Precautions” part of the June 2019 Actemra drug … More